Raymond James Financial reaffirmed their buy rating on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) in a report issued on Tuesday.

A number of other equities research analysts have also recently commented on the stock. BidaskClub raised shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 25th. Jefferies Group reaffirmed a buy rating and set a $16.00 price objective on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 24th. Finally, ValuEngine raised shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, September 18th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $26.20.

Bellicum Pharmaceuticals (NASDAQ:BLCM) traded down $0.65 on Tuesday, reaching $8.51. 753,200 shares of the company’s stock were exchanged, compared to its average volume of 592,773. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $16.44. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.03. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.03 million. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. Bellicum Pharmaceuticals’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.66) EPS. analysts expect that Bellicum Pharmaceuticals will post -2.93 EPS for the current year.

In other news, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 18.77% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at $164,000. Point72 Asset Management L.P. acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at $4,723,000. Schwab Charles Investment Management Inc. grew its stake in Bellicum Pharmaceuticals by 47.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after acquiring an additional 41,995 shares during the period. Harvey Capital Management Inc. acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at $458,000. Finally, D.A. Davidson & CO. grew its stake in Bellicum Pharmaceuticals by 17.4% in the 3rd quarter. D.A. Davidson & CO. now owns 47,650 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 7,050 shares during the period. 55.50% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/bellicum-pharmaceuticals-blcm-receives-buy-rating-from-raymond-james-financial/1761345.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.